[{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Exicure \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie Inc"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Bluejay","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Cavrotolimod","moa":"Toll-like-9 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ Bluejay","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ Bluejay"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Exicure","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"GPC-100","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exicure \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ GPCR Therapeutics"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Burixafor hydrobromide","moa":"||CXCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Exicure

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : GPC-100 (Burixafor HBr) is a novel small molecule CXCR4 antagonist, being investigated in patients with multiple myeloma.

                          Product Name : GPC-100

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 14, 2025

                          Lead Product(s) : Burixafor hydrobromide,Propranolol Hydrochloride,G-CSF

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The partnership aims to advance the clinical development of the company's mid-stage product GPC-201 (GPC-100+Propanalol) for treating patients suffering from Multiple Myeloma.

                          Product Name : GPC-201

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 26, 2024

                          Lead Product(s) : GPC-100,Propranolol Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : GPCR Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Bluejay will receive an exclusive license to all of Exicure’s relevant patents in hepatitis, including AST-008, designed for immuno-oncology applications.

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : Cavrotolimod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Bluejay

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid thera...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : $45.0 million

                          December 14, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : AbbVie Inc

                          Deal Size : $1,045.0 million

                          Deal Type : Termination

                          blank

                          05

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid thera...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : $20.0 million

                          December 14, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery

                          Sponsor : Ipsen

                          Deal Size : $1,020.0 million

                          Deal Type : Termination

                          blank

                          06

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous sq...

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          November 01, 2021

                          Lead Product(s) : Cavrotolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. Cavrotolimod is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          May 08, 2021

                          Lead Product(s) : Cavrotolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. The U.S. FDA has granted Orphan Drug Designation for cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma ...

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 03, 2021

                          Lead Product(s) : Cavrotolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $20.0 million

                          February 08, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery

                          Sponsor : Ipsen

                          Deal Size : $1,020.0 million

                          Deal Type : Collaboration

                          blank

                          10

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Cavrotolimod, the company’s SNA-enabled TLR9 agonist, is being developed for the treatment of solid tumors, in combination with anti-programmed cell death 1 (PD-1) therapy.

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          October 19, 2020

                          Lead Product(s) : Cavrotolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank